Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Equity Average (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Equity Average for 8 consecutive years, with $32.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 57.43% year-over-year to $32.8 million, compared with a TTM value of $32.8 million through Sep 2025, down 57.43%, and an annual FY2024 reading of $36.6 million, down 41.47% over the prior year.
  • Equity Average was $32.8 million for Q3 2025 at X4 Pharmaceuticals, up from $13.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $96.2 million in Q2 2021 and bottomed at $13.5 million in Q2 2025.
  • Average Equity Average over 5 years is $55.3 million, with a median of $59.3 million recorded in 2023.
  • The sharpest move saw Equity Average surged 49.41% in 2023, then crashed 71.81% in 2025.
  • Year by year, Equity Average stood at $66.5 million in 2021, then rose by 2.11% to $68.0 million in 2022, then fell by 12.66% to $59.3 million in 2023, then tumbled by 31.11% to $40.9 million in 2024, then fell by 19.79% to $32.8 million in 2025.
  • Business Quant data shows Equity Average for XFOR at $32.8 million in Q3 2025, $13.5 million in Q2 2025, and $22.5 million in Q1 2025.